Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
128.4 USD | -1.31% | +0.70% | +17.83% |
03:02pm | Merck: phase 3 trial in melanoma halted | CF |
02:05pm | Merck Ends Co-Formulation Arm of Keytruda High-Risk Melanoma Study | DJ |
- Stock Market
- Equities
- MRK Stock
- News Merck & Co., Inc.